Pharmacologic Substance
Novartis to Revise CRO Partnerships Amidst US Senate Bill Scrutiny
Novartis, CRO relationships, US Senate bill, Chinese companies, pharmaceutical industry, regulatory changes, partnership revisions
Senator Sanders Investigates Skyrocketing Costs of Novo Nordisk’s Diabetes and Weight Loss Drugs
Senator Bernie Sanders, Novo Nordisk, diabetes, weight loss, drug prices, Novos Ozempic, Wegovy, investigation, healthcare costs, affordability
FTC’s Proposed Noncompete Ban: A Game Changer for Biopharma Job Mobility
FTC, Noncompete Ban, Biopharma Jobs, Job Mobility, Employee Rights, Competition Law
Biogen’s Leqembi Gains Momentum: A Steady Pace in Market Growth
Biogen, Leqembi, Alzheimer’s disease, clinical trials, FDA approval, market growth, steady pace, neurology, healthcare, pharmaceuticals.
FDA Fast-Tracks Day One’s Innovative Therapy for Pediatric Brain Tumors
FDA, accelerated approval, Day One, targeted treatment, pediatric brain tumors, glioma, children, cancer treatment, innovative therapy.
Day One Outshines Novartis: FDA Approves Ojemda for Wider Pediatric Brain Tumor Treatment
Day One, Novartis, FDA, Ojemda, pediatric brain tumor, cancer treatment, clinical trials, pharmaceutical industry.
Novartis Boosts 2024 Sales Forecast, Gears Up for Major Cancer Drug Expansions
Novartis, 2024 sales outlook, cancer drugs, drug expansions, pharmaceutical industry, healthcare, oncology.
Projected $270 Billion Orphan Drug Market by 2028: A Comprehensive Analysis of Leading Players J&J, Vertex, and Roche
Orphan drugs, rare diseases, J&J, Vertex, Roche, market growth, 2028, Evaluate
Xaira: The Billion-Dollar AI-Powered Drug Discovery Startup Revolutionizing Healthcare
Xaira, AI, drug discovery, healthcare, startup, funding, billion-dollar, revolutionizing, pharmaceuticals, biotechnology.
Roche Streamlines Portfolio, Prioritizes High-Impact Projects After Pipeline Reduction
Roche, pharmaceuticals, pipeline, portfolio optimization, high-impact projects, strategic decision, drug development